The Pharmacology and Toxicology of Three New Biologic Agents Used in Pulmonary Medicine

References

• Allen R. P., Albertson T. E. Steroids and biologic agents in the intensive care unit. Crit Care Clin 1991; 7: 695–711
   PubMed Web of Science ®Google Scholar
• Knowles M. R. New therapies for cystic fibrosis. Introduction. Chest 1995; 107: 59S–60S
   PubMed Web of Science ®Google Scholar
• Potter J., Matthews L. W., Lem J., Spector S. The composition of pulmonary secretions from patients with and without cystic fibrosis. Am J Dis Child 1960; 100: 493–494
   Google Scholar
• Picot R., Das I., Reid L. Pus, deoxyribonucleic acid, and sputum viscosity. Thorax 1978; 33: 235–242
   PubMed Web of Science ®Google Scholar
• Shak S., Capon D. J., Hellmiss R., Marsters S. A., Baker C. L. Recombinant human DNase I reduces viscosity of cystic fibrosis sputum. Proc Natl Acad Sci 1990; 87: 9188–9192
   PubMed Web of Science ®Google Scholar
• Chernick W. S., Barbero G. J., Eichel H. J. In vitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatrics 1961; 27: 589–596
   PubMed Web of Science ®Google Scholar
• Elmes P. C., White J. C. Deoxyribonuclease in the treatment of purulent bronchitis. Thorax 1953; 8: 295–300
   PubMed Web of Science ®Google Scholar
• Salomon A., Herchfus J. A., Segal M. S. Aerosols of pancreatic dornase in bronchopulmonary disease. Ann Allergy 1954; 12: 71–79
   PubMedGoogle Scholar
• Fraber S. M., Pharr S. L., Wood D. A., Frost J. K. Enzymatic therapy in diseases of the chest clinical and cytologic aspects. Lab Invest 1955; 4: 362–370
   PubMed Web of Science ®Google Scholar
• Spier R., Witebsky E., Paine J. R. Aerosolized pancreatic dornase and antibiotics in pulmonary infections. JAMA 1961; 178: 878–886
   PubMed Web of Science ®Google Scholar
• Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA 1968; 205: 312–313
   PubMed Web of Science ®Google Scholar
• Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis 1968; 98: 697–698
   PubMed Web of Science ®Google Scholar
• Aitken M. L., Burke W., McDonald G., Shak S., Montgomery A. B., Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 1992; 267: 1947–1951
   PubMed Web of Science ®Google Scholar
• Hubbard R. C., McElvaney N. G., Birrer P., et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992; 326: 812–815
   PubMed Web of Science ®Google Scholar
• Ramsey B. W., Astley S. J., Aitken M. L., et al. Efficacy and safety of short‐term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145–151
   PubMed Web of Science ®Google Scholar
• Ranasinha C., Assoufi B., Shak S., et al. Efficacy and safety of short‐term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199–202
   PubMed Web of Science ®Google Scholar
• Green J. D. Pharmaco‐toxicological expert report Pulmozyme* rhDNase, Genentech, Inc. Human Expl Toxicol 1994; 13: S1–S42
   PubMed Web of Science ®Google Scholar
• Fuchs H. J., Borowitz D. S., Christiansen D. H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637–642
   PubMed Web of Science ®Google Scholar
• Shak S. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest 1995; 107: 65S–70S
   PubMed Web of Science ®Google Scholar
• Hodson M. E. Aerosolized dornase alfa (rhDNase) for the therapy of cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 570–574
   PubMed Web of Science ®Google Scholar
• Wewers M. D., Casolaro M. A., Sellers S. E., et al. Replacement therapy for alpha, antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055–1062
   PubMed Web of Science ®Google Scholar
• vanSteenbergen W. Alpha‐1‐antitrypsindeficiency: an overview. Acta Clin Belg 1993; 48: 171–189
   PubMed Web of Science ®Google Scholar
• Coan M. H. Purification of alpha‐1‐proteinase inhibitor. Preparation and properties of a therapeutic concentrate. Am J Med 1988; 84: 32–36
   PubMed Web of Science ®Google Scholar
• Clark J. A., Gross T. P. Pain and cyanosis associated with alpha 1‐proteinase inhibitor. Am J Med 1992; 92: 621–626
   PubMed Web of Science ®Google Scholar
• Nagai A., Aoshiba Y., Ishihara Y., et al. Administration of alpha 1‐proteinase inhibitor ameliorates bleomycin‐induced pulmonary fibrosis in hamsters. Am Rev Respir Dis 1992; 145: 651–656
   PubMed Web of Science ®Google Scholar
• Wachter A. M., Lezdey J. Treatment of atopic dermatitis with alpha 1‐proteinase inhibitor. Ann Allergy 1992; 69: 407–414
   PubMedGoogle Scholar
• Physicians' Desk Reference49th Edition. Medical Economics Data Production Company, Montvale 1995; 1708–1710
   Google Scholar
• Hubbard R. C., Sellers S., Czerski D., Stephens L., Crystal R. G. Biochemical efficacy and safety of monthly augmentation therapy for a.‐antitrypsin deficiency. JAMA 1988; 260: 1259–1264
   PubMed Web of Science ®Google Scholar
• Hubbard R. C., Brantly M. L., Seller S. E., Mitchell M. E., Crystal R. G. Anti‐neutrophil‐elastase defenses of the lower respiratory tract in alpha 1‐antitrypsin deficiency directly augmented with an aerosol of alpha 1‐antitrypsin. Ann Int Med 1989; 111: 206–212
   PubMed Web of Science ®Google Scholar
• Alvarez J., Alvarez L., Escudero C., Gilsanz F., de Oya S., Castillo‐Olivares J. L. Hemodynamic and morphologic alterations after experimental administration of protamine sulfate. Am J Surg 1988; 155: 735–740
   PubMed Web of Science ®Google Scholar
• Klein R., Dumble L. J. Transmission of Creutzfeldt‐Jakob disease by blood transfusion. Lancet 1993; 341: 768
   PubMed Web of Science ®Google Scholar
• Matthews W. B. Transmission of Creutzfeldt‐Jakob disease. Lancet 1994; 343: 1575–1576
   PubMed Web of Science ®Google Scholar
• Heye N., Hensen S., Muller N. Creutzfeldt‐Jakob disease and blood transfusion. Lancet 1994; 343: 298–299
   PubMed Web of Science ®Google Scholar
• Esmonde T. F. G., Will R. G., Slattery J. M., et al. Creutzfeldt‐Jakob disease and blood transfusion. Lancet 1993; 341: 205–207
   PubMed Web of Science ®Google Scholar
• Wessel D. L., Adatia I., Thompson J. E., Hickey P. R. Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension. Crit Care Med 1994; 22: 930–938
   PubMed Web of Science ®Google Scholar
• Palmer R. M. J., Ferridge A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium‐derived relaxing factor. Nature 1987; 327: 524–526
   PubMed Web of Science ®Google Scholar
• Ignarro L. J., Buga G. M., Wood K. S., Byrns R. E., Chaudhuri G. Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265–9269
   PubMed Web of Science ®Google Scholar
• Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–142
   PubMed Web of Science ®Google Scholar
• Barnes P. J. Nitric oxide and airway. Eur Respir J 1993; 6: 163–165
   PubMed Web of Science ®Google Scholar
• Gaston B., Drazen J. M., Los Calzo J., Stamler J. S. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994; 149: 538–551
   PubMed Web of Science ®Google Scholar
• Palmer R. M., Ashton D. S., Moncada S. Vascular endothelial cells synthesize nitric oxide from L‐arginine. Nature 1988; 333: 664–666
   PubMed Web of Science ®Google Scholar
• Moncada S., Higgs A. The L‐arginine‐nitric oxide pathway. N Engl J Med 1993; 329: 2002–2012
   PubMed Web of Science ®Google Scholar
• Star R. A. Southwestern Internal Medicine conference; nitric oxide. Am J Med Sci 1993; 306: 348–358
   PubMed Web of Science ®Google Scholar
• Kubes P., Suzuki M., Granger D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 1991; 88: 4651–4655
   PubMed Web of Science ®Google Scholar
• Rossaint R., Pison U., Gerlach H., Falke K. J. Inhaled nitric oxide: its effects on pulmonary circulation and airway smooth muscle cells. Eur Heart J 1993; 14(Suppl 1)133–140
   PubMed Web of Science ®Google Scholar
• Alving K., Fornheim C., Weitzberg E., Lundberg J. M. Nitric oxide mediates cigarette smoke‐induced vasodilatory responses in the lung. Acta Physiol Scand 1992; 146: 407–408
   PubMedGoogle Scholar
• Belvisi M. G., Stretton C. D., Yacoub M., Barnes P. J. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharmacol 1992; 210: 221–222
   PubMed Web of Science ®Google Scholar
• Hogman M., Frostell C. G., Hedenstrom H., Heden‐stierna G. Inhalation of nitric oxide modulates adult human bronchial tone. Am Rev Respir Dis 1993; 148: 1474–1478
   PubMed Web of Science ®Google Scholar
• Adatia I., Lillehei C., Arnold J. H., Thompson J. E., Palazzo R., Fackler J. C., Wessel D. L. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994; 57: 1311–1318
   PubMed Web of Science ®Google Scholar
• Kinsella J. P., Neish S. R., Shaffer E., Abman S. H. Low‐dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340: 819–820
   PubMed Web of Science ®Google Scholar
• Finer N. N., Etches P. C., Kanstra B., Tierney A. J., Peliowski A., Ryan C. A. Inhaled nitric oxide in infants referred for extra corporeal membrane oxygenation dose response. J Pediatr 1994; 124: 302–308
   PubMed Web of Science ®Google Scholar
• Kinsella J. P., Abman S. H. Inhalational nitric oxide therapy for persistent pulmonary hypertension of the newborn. Pediatrics 1993; 91: 997–998
   PubMed Web of Science ®Google Scholar
• Roberts J. D., Lang P., Bigatello L. M., Vlahakes G. J., Zapol W. M. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447–453
   PubMed Web of Science ®Google Scholar
• Winberg P., Lundell B. P. W., Gustafsson L. E. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J 1994; 71: 282–286
   PubMedGoogle Scholar
• Miller O. I., Celermajer D. S., Deanfield J. E., Macrae D. J. Very‐low‐dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994; 108: 487–494
   PubMed Web of Science ®Google Scholar
• Journois D., Pouard P., Mauriat P., Malhere T., Vouhe P., Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 1994; 107: 1129–1135
   PubMed Web of Science ®Google Scholar
• Kouyaoumdjian C., Adnot S., Levame M., Eddahibi S., Bousbaa H., Raffestin B. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J Clin Invest 1994; 94: 578–584
   PubMed Web of Science ®Google Scholar
• Etches P. C., Finer N. N., Barrington K. J., Graham A. J., Chan W. K. Y. Nitric oxide reverses acute hypoxic pulmonary hypertension in the newborn piglet. PediatrRes 1994; 35: 15–19
   Google Scholar
• Nelin L. D., Moshin J., Thomas C. J., Sasidharan P., Dawson C. A. The effect of inhaled nitric oxide on the pulmonary circulation of the neonatal pig. Pediatr Res 1994; 35: 20–24
   PubMed Web of Science ®Google Scholar
• Frostell C., Fratacci M. ‐D., Wain J. C., Jones R., Zapol W. M. Inhaled nitric oxide a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83: 2038–2047
   PubMed Web of Science ®Google Scholar
• Fratacci M. ‐D., Frostell C. G., Chew T. ‐Y., Wain J. C., Robinson D. R., Zapol W. M. Inhaled nitric oxide a selective pulmonary vasodilator of heparin‐protamine vasoconstriction in sheep. Anesthesiology 1991; 75: 990–999
   PubMed Web of Science ®Google Scholar
• Tonz M., von Segesser L. K., Turina M. Selective pulmonary vasodilatation with inhaled nitric oxide. J Thorac Cardiovasc Surg 1993; 105: 760–762
   PubMed Web of Science ®Google Scholar
• Rich G. F., Lowson S. M., Johns R. A., Daugherty M. O., Uncles D. R. Inhaled nitric oxide selectively decreases pulmonary vascular resistance without impairing oxygenation during one‐lung ventilation in patients undergoing cardiac surgery. Anesthesiology 1991; 80: 57–62
   Web of Science ®Google Scholar
• Pepke‐Zaba J., Higenbottam T. W., Dinh‐Xuan A. T., Stone D., Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173–1174
   PubMed Web of Science ®Google Scholar
• Channick R. N., Hoch R. C., Newhart J. W., Johnson F. W., Smith C. M. Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end‐stage pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 811–814
   PubMed Web of Science ®Google Scholar
• Fratacci M. D., Defouilloy C., Andrivet P., Kouyoumdjian C., Sediame S., Herigant R., Adnot S. Responses to infusion of acetylcholine and inhalation acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am Rev Respir Dis 1992; 145: A722
   PubMedGoogle Scholar
• Moinard J., Manier G., Pillet O., Costaing Y. Effect of inhaled nitric oxide on hemodynamics and VA/Q inequalities in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149: 1482–1487
   PubMed Web of Science ®Google Scholar
• Weitzenblum E., Kessler R., Oswald M., Fraisse P. Medical treatment of pulmonary hypertension in chronic lung disease. Eur Respir J 1994; 7: 148–152
   PubMed Web of Science ®Google Scholar
• Lunn R. J. Inhaled nitric oxide therapy. Mayo Clin Proc 1995; 70: 247–255
   PubMed Web of Science ®Google Scholar
• Cioffi W. G., Ogura H. Inhaled nitric oxide in acute lung disease. New Horizons 1995; 3: 73–85
   PubMedGoogle Scholar
• Rovira I., Chen T. Y., Winkler M., Kawai N., Bloch K. D., Zapol W. M. Effects of inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of ARDS. J Appl Physiol 1994; 76: 345–355
   PubMed Web of Science ®Google Scholar
• Gerlach H., Rossaint R., Pappert D., Falke K. J. Time‐course and dose‐response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993; 23: 499–502
   PubMed Web of Science ®Google Scholar
• Abman S. H., Griebel J. L., Parker D. K., Schmidt J. M., Swanton D., Kinsella J. P. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratoryfailure. J Pediatr 1994; 124: 881–888
   PubMed Web of Science ®Google Scholar
• Rossaint R., Falke K. J., Lopez F., Slama K., Pison U., Zapol W. M. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399–405
   PubMed Web of Science ®Google Scholar
• Gerlach H., Pappert D., Lewandowski K., Rossaint R., Falke K. J. Longterm inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome. Intensive Care Med 1993; 19: 443–449
   PubMed Web of Science ®Google Scholar
• Rossaint R., Gerlach H., Schmidt‐Ruhnke H., Pappert D., Lewandowski Y., Stendel W., Falke K. Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995; 107: 1107–1115
   PubMed Web of Science ®Google Scholar
• Chiodi H., Mohler J. G. Effects of exposure of blood hemoglobin to nitric oxide. Environ Res 1985; 37: 355–363
   PubMed Web of Science ®Google Scholar
• Greenbaum R., Bay J., Hargreaves M. D., Kain M. L., Kelman G. R., Nunn J. F., Prys‐Roberts C., Siebold K. Effects of higher oxides of nitrogen on the anaesthetized dog. Br J Anaesth 1967; 39: 393–404
   PubMed Web of Science ®Google Scholar
• Maeda N., Imaizumi K., Kon Y., Shiga T. A kinetic study on functional impairment of nitric oxide‐exposed rat erythrocytes. Environ Health Perspect 1987; 73: 171–177
   PubMed Web of Science ®Google Scholar
• Clutton‐Brock I. Two cases of poisoning by contamination of nitrous oxide with higher oxides of nitrogen during anaesthesia. Br J Anaesth 1967; 39: 388–392
   PubMed Web of Science ®Google Scholar
• Toohill C. The chemistry of the in vivo reaction between haemoglobin and various oxides of nitrogen. Br J Anaesth 1967; 39: 405–412
   PubMed Web of Science ®Google Scholar
• Oda H., Kusumoto S., Nakajima T. Nitrosyl‐hemoglobin formation in the blood of animals exposed to nitric oxide. Arch Environ Health 1975; 30: 453–455
   PubMed Web of Science ®Google Scholar
• Scott E. M., Hoskin D. D. Hereditary methemoglobinemia in Alaskan Eskimos and Indians. Blood 1958; 13: 795–802
   PubMed Web of Science ®Google Scholar
• von Niebar G., Wagner H. M., Krekeler H. Investigation of the acute effects of nitrogen monoxides on lung function in man. Proceedings of the Third International Clean Air Congress. VDI‐Verlag GmbH, Dusseldorf, Dusseldorf 1973; A14–A16
   Google Scholar
• Morrow P. E. Toxicological data on NOx: an overview. J Tox Environ Health 1984; 13: 205–227
   PubMed Web of Science ®Google Scholar
• Bylin G., Hedenstierna G., Lindvall T., Sundin B. Ambient nitrogen dioxide concentrations increase bronchial responsiveness in subjects with mild asthma. Eur RespirJ 1988; 1: 606–612
   PubMed Web of Science ®Google Scholar
• Stephens R. J., Freeman G., Evans M. J. Early responses of lungs to low levels of nitrogen dioxide. Arch Environ Health 1972; 24: 160–179
   PubMedGoogle Scholar
• Muller B., Barth P., Von Wichert P. Structural and functional impairment of surfactant protein A after exposure to nitrogen dioxide in rats. Am J Physiol 1992; 263, (Lung Cell Mol Physiol):L177‐L184
   Google Scholar
• Radi R., Beckman J. S., Bush K. M., Freeman B. A. Peroxynitrite‐induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophy 1991; 288: 481–487
   PubMed Web of Science ®Google Scholar
• Radi R., Beckman J. S., Bush K. M., Freeman B. A. Peroxynitrite oxidation of sulfhydrls the cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991; 266: 4244–4250
   PubMed Web of Science ®Google Scholar
• Bassenge E. Antiplatelet effect of endothelium‐derived relaxing factor and nitric oxide donors. Eur Heart J 1992; 12: 12–15, suppl
   Web of Science ®Google Scholar
• Hogman M., Frostell C., Arnberg H., Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet 1993; 341: 1664–1665
   PubMed Web of Science ®Google Scholar
• Bocchi E. A., Bacal F., Auler J. O., Carmone M. J., Bellotti G., Pileggi E. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 1994; 74: 70–72
   PubMed Web of Science ®Google Scholar
• Semigran M. J., Cockrill B. A., Kacmarek R., Thompson B. T., Zapol W. M., Dec G. W. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994; 24: 982–988
   PubMed Web of Science ®Google Scholar